Raymond James Financial
LGND icon

Raymond James Financial’s Ligand Pharmaceuticals LGND Stock Holding History

Raymond James Financial’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.65M Sell
18,258
-498
-3% -$98.5K ﹤0.01% 2853
2025
Q4 		$3.55M Sell
18,756
-104
-0.6% -$20K ﹤0.01% 2798
2025
Q3 		$3.34M Sell
18,860
-1,237
-6% -$184K ﹤0.01% 2770
2025
Q2 		$2.28M Sell
20,097
-40
-0.2% -$4.28K ﹤0.01% 2976
2025
Q1 		$2.12M Sell
20,137
-1,693
-8% -$191K ﹤0.01% 2948
2024
Q4 		$2.34M Buy
+21,830
New +$2.47M ﹤0.01% 2852

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Raymond James Financial's LGND Position: Q1 2026 in Review

Raymond James Financial reduced its Ligand Pharmaceuticals (LGND) stake by 2.7% in Q1 2026, selling an estimated $98.5K and leaving 18,258 shares worth $3.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2853.

Raymond James Financial first reported a position in LGND in Q4 2024 and has held it in 6 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Raymond James Financial held 18,258 shares of Ligand Pharmaceuticals worth $3.65M as of Q1 2026.
  • Raymond James Financial sold 498 Ligand Pharmaceuticals shares in Q1 2026, an estimated $98.5K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2853 holding.
  • Raymond James Financial first reported a position in Ligand Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.